Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

By S. Spranger, R. Bao, T. Gajewski. Nature, 2015

2,500 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/01302d564b80ca6d02545b9d9d30577355fde968

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020, background): “Tumor infiltration or exclusion is another determinant of immune activity (Spranger et al., 2015).”
Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition (2016, neutral): “This would be consistent with recently published data showing that b-catenin expression in melanoma lesions alters chemokine production, thereby compromising DC and T cell recruitment (Spranger et al., 2015).”
Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy (2017, methodology): “Without endogenously generated effector T cells, there was no baseline T cell infiltration into tumors, which led to resistance to checkpoint blockade immunotherapy (Spranger et al., 2015).”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade (2017, background): “, WNT/β-catenin pathway activation) (25), failure of T cell priming (amenable to reversal by tumor-specific vaccines, oncolytic viruses, or adoptive T cell therapy), or the activity of other cells in the tumor microenvironment, such as stromal cells (26) or vascular endothelial cells (27).”
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab (2017, background): “Further, the location of CD8+ T cells at the invasive margin of tumors may indicate an effective immune response (Chen et al., 2016; Spranger et al., 2015; Tumeh et al., 2014).”
Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, positive): “Using a genetically engineered mouse model they showed that melanomas arising from mice with active βcatenin were characterized by an almost complete absence of both CD8+ T cells and cDC1 subsets (37).”